Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, filed a Form 4 on November 19, 2026, disclosing a sale of 192 shares of common stock on November 17, 2026, to cover tax withholding obligations connected to vesting RSUs.
Key Highlights
- Reporting person: Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NASDAQ:NKTR)
- Transaction: 192 shares of common stock disposed of (transaction code S) on November 17, 2026
- Purpose: According to the filing, the shares were sold "to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person"
- Weighted average price: $35.85 per share, with individual trades ranging from $35.57 to $36.31
- Remaining beneficial ownership: 9,378 shares of common stock held directly following the transaction
Zalevsky RSU Tax-Withholding Sale at Nektar Therapeutics
Jonathan Zalevsky, serving as Chief R&D Officer at Nektar Therapeutics, reported the disposal of 192 shares of the company's common stock on November 17, 2026. The filing, submitted to the SEC on November 19, 2026, was signed by Elizabeth Zhang as Attorney-in-Fact. The transaction carried code "S," indicating a sale, and was recorded at a weighted average price of $35.85 per share.
According to the filing, the sale was executed across multiple trades at prices ranging from $35.57 to $36.31. The filing further states that the reporting person "undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer." The filing explicitly characterizes the sale as non-discretionary, attributing it solely to mandatory tax withholding tied to RSU vesting.
Following the reported transaction, Zalevsky directly beneficially owned 9,378 shares of Nektar Therapeutics common stock, according to the filing. No derivative securities were reported in Table II of the filing.
What Was Disclosed
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky disclosed a sale of 192 common shares on November 17, 2026, at a weighted average of $35.85, solely for RSU-related tax withholding, leaving him with 9,378 shares directly owned.




Please wait processing your request...